209 related articles for article (PubMed ID: 35013261)
1. Lipidomic profiling of human serum enables detection of pancreatic cancer.
Wolrab D; Jirásko R; Cífková E; Höring M; Mei D; Chocholoušková M; Peterka O; Idkowiak J; Hrnčiarová T; Kuchař L; Ahrends R; Brumarová R; Friedecký D; Vivo-Truyols G; Škrha P; Škrha J; Kučera R; Melichar B; Liebisch G; Burkhardt R; Wenk MR; Cazenave-Gassiot A; Karásek P; Novotný I; Greplová K; Hrstka R; Holčapek M
Nat Commun; 2022 Jan; 13(1):124. PubMed ID: 35013261
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
3. Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and Sphingomyelins and Ovarian Cancer Risk: A 23-Year Prospective Study.
Zeleznik OA; Clish CB; Kraft P; Avila-Pacheco J; Eliassen AH; Tworoger SS
J Natl Cancer Inst; 2020 Jun; 112(6):628-636. PubMed ID: 31593240
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic profiling suggests long chain ceramides and sphingomyelins as a possible diagnostic biomarker of epithelial ovarian cancer.
Kozar N; Kruusmaa K; Bitenc M; Argamasilla R; Adsuar A; Goswami N; Arko D; Takač I
Clin Chim Acta; 2018 Jun; 481():108-114. PubMed ID: 29481776
[TBL] [Abstract][Full Text] [Related]
5. Serum lipids profiling perturbances in patients with ischemic heart disease and ischemic cardiomyopathy.
Yang L; Wang L; Deng Y; Sun L; Lou B; Yuan Z; Wu Y; Zhou B; Liu J; She J
Lipids Health Dis; 2020 May; 19(1):89. PubMed ID: 32386519
[TBL] [Abstract][Full Text] [Related]
6. Serum lipidome screening in patients with stage I non-small cell lung cancer.
Klupczynska A; Plewa S; Kasprzyk M; Dyszkiewicz W; Kokot ZJ; Matysiak J
Clin Exp Med; 2019 Nov; 19(4):505-513. PubMed ID: 31264112
[TBL] [Abstract][Full Text] [Related]
7. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
[TBL] [Abstract][Full Text] [Related]
8. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
[TBL] [Abstract][Full Text] [Related]
9. Detection of pancreatic cancer with normal carbohydrate antigen 19-9 using protein chip technology.
Jin XL; Xu B; Wu YL
World J Gastroenterol; 2014 Oct; 20(40):14958-64. PubMed ID: 25356057
[TBL] [Abstract][Full Text] [Related]
10. Lipidomic characterization of exosomes isolated from human plasma using various mass spectrometry techniques.
Peterka O; Jirásko R; Chocholoušková M; Kuchař L; Wolrab D; Hájek R; Vrána D; Strouhal O; Melichar B; Holčapek M
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 May; 1865(5):158634. PubMed ID: 31978556
[TBL] [Abstract][Full Text] [Related]
11. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
[TBL] [Abstract][Full Text] [Related]
12. High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm.
Aronsson L; Andersson R; Bauden M; Andersson B; Bygott T; Ansari D
Scand J Gastroenterol; 2018 Dec; 53(12):1597-1603. PubMed ID: 30509115
[TBL] [Abstract][Full Text] [Related]
13. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer.
Cheng F; Wen Z; Feng X; Wang X; Chen Y
Life Sci; 2020 Nov; 260():118489. PubMed ID: 32976882
[TBL] [Abstract][Full Text] [Related]
14. Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico.
Flores YN; Amoon AT; Su B; Velazquez-Cruz R; Ramírez-Palacios P; Salmerón J; Rivera-Paredez B; Sinsheimer JS; Lusis AJ; Huertas-Vazquez A; Saab S; Glenn BA; May FP; Williams KJ; Bastani R; Bensinger SJ
Lipids Health Dis; 2021 Oct; 20(1):136. PubMed ID: 34629052
[TBL] [Abstract][Full Text] [Related]
15. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
17. Standardized peptidome profiling of human serum for the detection of pancreatic cancer.
Zapico-Muñiz E; Farré-Viladrich A; Rico-Santana N; González-Sastre F; Mora-Brugués J
Pancreas; 2010 Nov; 39(8):1293-8. PubMed ID: 20924310
[TBL] [Abstract][Full Text] [Related]
18. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
Luo G; Liu C; Guo M; Cheng H; Lu Y; Jin K; Liu L; Long J; Xu J; Lu R; Ni Q; Yu X
Ann Surg; 2017 Apr; 265(4):800-805. PubMed ID: 28267695
[TBL] [Abstract][Full Text] [Related]
19. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
[TBL] [Abstract][Full Text] [Related]
20. Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques.
Velstra B; Vonk MA; Bonsing BA; Mertens BJ; Nicolardi S; Huijbers A; Vasen H; Deelder AM; Mesker WE; van der Burgt YE; Tollenaar RA
J Cancer Res Clin Oncol; 2015 Mar; 141(3):531-41. PubMed ID: 25240825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
